39 related articles for article (PubMed ID: 31882297)
1. Disruption of CXCR6 Ameliorates Kidney Inflammation and Fibrosis in Deoxycorticosterone Acetate/Salt Hypertension.
Wu Y; An C; Jin X; Hu Z; Wang Y
Sci Rep; 2020 Jan; 10(1):133. PubMed ID: 31924817
[TBL] [Abstract][Full Text] [Related]
2. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
Yahoo N; Dudek M; Knolle P; Heikenwälder M
J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD122 antibody restores specific CD8
Lacotte S; Slits F; Moeckli B; Peloso A; Koenig S; Tihy M; El Hajji S; Gex Q; Rubbia-Brandt L; Toso C
Oncoimmunology; 2023; 12(1):2184991. PubMed ID: 36891258
[TBL] [Abstract][Full Text] [Related]
4. CXCR6 is required for antitumor efficacy of intratumoral CD8
Wang B; Wang Y; Sun X; Deng G; Huang W; Wu X; Gu Y; Tian Z; Fan Z; Xu Q; Chen H; Sun Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462326
[TBL] [Abstract][Full Text] [Related]
5. Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future.
Butt NU; Baytas SN
Curr Pharm Des; 2023; 29(1):2-14. PubMed ID: 36529919
[TBL] [Abstract][Full Text] [Related]
6. Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.
Kamal MA; Mandour YM; Abd El-Aziz MK; Stein U; El Tayebi HM
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080304
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.
Li S; Han W; He Q; Zhang W; Zhang Y
Contrast Media Mol Imaging; 2022; 2022():6533628. PubMed ID: 35965618
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma levels of CXCL16 in severe COVID-19 patients.
Smieszek SP; Polymeropoulos VM; Polymeropoulos CM; Przychodzen BP; Birznieks G; Polymeropoulos MH
Cytokine; 2022 Apr; 152():155810. PubMed ID: 35121493
[TBL] [Abstract][Full Text] [Related]
9. Functions of CXC chemokines as biomarkers and potential therapeutic targets in the hepatocellular carcinoma microenvironment.
Wang J; Zhang C; Chen X; Li Y; Li A; Liu D; Li F; Luo T
Transl Cancer Res; 2021 May; 10(5):2169-2187. PubMed ID: 35116536
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils as potential therapeutic targets in hepatocellular carcinoma.
Geh D; Leslie J; Rumney R; Reeves HL; Bird TG; Mann DA
Nat Rev Gastroenterol Hepatol; 2022 Apr; 19(4):257-273. PubMed ID: 35022608
[TBL] [Abstract][Full Text] [Related]
11. Behavior of Chemokine Receptor 6 (CXCR6) in Complex with CXCL16 Soluble form Chemokine by Molecular Dynamic Simulations: General Protein‒Ligand Interaction Model and 3D-QSAR Studies of Synthetic Antagonists.
Aguilera-Durán G; Romo-Mancillas A
Life (Basel); 2021 Apr; 11(4):. PubMed ID: 33920834
[TBL] [Abstract][Full Text] [Related]
12. The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases.
Korbecki J; Bajdak-Rusinek K; Kupnicka P; Kapczuk P; Simińska D; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800554
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in treatment of hepatocellular carcinoma.
Chen Z; Xie H; Hu M; Huang T; Hu Y; Sang N; Zhao Y
Am J Cancer Res; 2020; 10(9):2993-3036. PubMed ID: 33042631
[TBL] [Abstract][Full Text] [Related]
14. Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma.
Peddibhotla S; Hershberger PM; Jason Kirby R; Sugarman E; Maloney PR; Hampton Sessions E; Divlianska D; Morfa CJ; Terry D; Pinkerton AB; Smith LH; Malany S
Bioorg Med Chem Lett; 2020 Feb; 30(4):126899. PubMed ID: 31882297
[TBL] [Abstract][Full Text] [Related]
15. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma.
Gao Q; Zhao YJ; Wang XY; Qiu SJ; Shi YH; Sun J; Yi Y; Shi JY; Shi GM; Ding ZB; Xiao YS; Zhao ZH; Zhou J; He XH; Fan J
Cancer Res; 2012 Jul; 72(14):3546-56. PubMed ID: 22710437
[TBL] [Abstract][Full Text] [Related]
16. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway.
Gou H; Liu S; Liu L; Luo M; Qin S; He K; Yang X
Front Immunol; 2022; 13():1095915. PubMed ID: 36605219
[TBL] [Abstract][Full Text] [Related]
18. CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer.
Deng L; Chen N; Li Y; Zheng H; Lei Q
Biochim Biophys Acta; 2010 Aug; 1806(1):42-9. PubMed ID: 20122997
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
